tiprankstipranks
Trending News
More News >

FDA Sets PDUFA Date for Xspray Pharma’s Dasynoc® Application

Story Highlights
FDA Sets PDUFA Date for Xspray Pharma’s Dasynoc® Application

Confident Investing Starts Here:

Xspray Pharma AB ( (SE:XSPRAY) ) just unveiled an announcement.

Xspray Pharma AB has received acknowledgment from the FDA for its re-submitted New Drug Application for Dasynoc®, with a PDUFA date set for October 7, 2025. This development is crucial for the company’s plans to launch Dasynoc® in the US market, offering a new dasatinib drug option for ALL and CML patients, pending market approval.

More about Xspray Pharma AB

Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors (PKIs) using its patented HyNap™ technology platform. The company aims to lead in the oncology market segment by offering enhanced PKIs for cancer treatment. Its lead product, Dasynoc®, is an amorphous form of dasatinib, designed to be bioequivalent at a lower dose and compatible with proton pump inhibitors, providing significant advantages for patients with CML and ALL.

Average Trading Volume: 19,708

Current Market Cap: SEK1.03B

See more insights into XSPRAY stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App